A randomized clinical trial of the effects of isosorbide mononitrate on bone formation and resorption in post-menopausal women: A pilot study (Human Reproduction (2006) vol. 21 (1320-1324) 10.1093/humrep/dei487);A randomized clinical trial of the effects of isosorbide mononitrate on bone formation and resorption in post-menopausal women: A pilot study (Retraction in: Human Reproduction (2006) 21:10 (2466))

Human Reproduction

Volumn 21, Issue 5, 2006, Pages 1320-1324

  Nabhan, Ashraf F I ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Bone turnover; Isosorbide mononitrate; Nitric oxide; Post menopausal osteoporosis; Randomized trial

Indexed keywords

ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; BIOLOGICAL MARKER; CALCIUM CARBONATE; ISOSORBIDE DINITRATE; NITRIC OXIDE; VITAMIN D;

ADULT; ARTICLE; BONE DENSITY; BONE MINERAL; BONE TURNOVER; CALCULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG MECHANISM; EGYPT; ENZYME BLOOD LEVEL; FEMALE; HEADACHE; HIP; HUMAN; OSSIFICATION; OSTEOLYSIS; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PILOT STUDY; POSTMENOPAUSE OSTEOPOROSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; URINALYSIS;

EID: 33645832193     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/del359     Document Type: Erratum

References (24)

1. Chow JW (2000) Role of nitric oxide and prostaglandins in the bone formation response to mechanical loading. Exerc Sport Sci Rev 28 (4),185-188.
2. Cicinelli E, Ignarro LJ, Matteo MG, Galantino P, Schonauer LM and Falco N (1999) Effects of estrogen replacement therapy on plasma levels of nitric oxide in postmenopausal women. Am J Obstet Gynecol 180 (2 Part 1),334-339.
3. Clowes JA and Eastell R (2000) The role of bone turnover markers and risk factors in the assessment of osteoporosis and fracture risk. Baillieres Best Pract Res Clin Endocrinol Metab 14 (2),213-232.
4. Csont T and Ferdinandy P (2005) Cardioprotective effects of glyceryl trinitrate: Beyond vascular nitrate tolerance. Pharmacol Ther 105 (1),57-68.
5. Garnero P and Delmas PD (2004) Contribution of bone mineral density and bone turnover markers to the estimation of risk of osteoporotic fracture in postmenopausal women. J Musculoskelet Neuronal Interact 4 (1),50-63.
6. Greenblatt D (2005) Treatment of postmenopausal osteoporosis. Pharmacotherapy 25 (4),574-584.
7. Hannon RA and Eastell R (2003) Biochemical markers of bone turnover and fracture prediction. J Br Menopause Soc 9 (1),10-15.
8. Hao YJ, Tang Y, Chen FB and Pei FX (2005) Different doses of nitric oxide donor prevent osteoporosis in ovariectomized rats. Clin Orthop Relat Res 435,226-231.
9. Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE and Ross PD (2002) Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 87 (4),1586-1592.
10. Hukkanen M, Platts LA, Lawes T, Girgis SI, Konttinen YT, Goodship AE, MacIntyre I and Polak JM (2003) Effect of nitric oxide donor nitroglycerin on bone mineral density in a rat model of estrogen deficiency-induced osteopenia. Bone 32 (2),142-149.
11. Jung JY, Lin AC, Ramos LM, Faddis BT and Chole RA (2003) Nitric oxide synthase I mediates osteoclast activity in vitro and in vivo. J Cell Biochem 89 (3),613-621.
12. Kalinowski L, Dobrucki LW and Malinski T (2001) Nitric oxide as a second messenger in parathyroid hormone-related protein signaling. J Endocrinol 170 (2),433-440.
13. Looker AC, Bauer DC, Chesnut CH III, Gundberg CM, Hochberg MC, Klee G et al. (2000) Clinical use of biochemical markers of bone remodeling: current status and future directions. Osteoporos Int 11 (6),467-480.
14. Marquis P, Le Gal M, Francillon A and Andre-Fouet X (2001) [Quality of life and angina pectoris. Comparison of the effects of 2 nitrate derivatives administered discontinuously: Transdermal 10 mg nitroglycerine patch (12 hours) and long-acting oral 40 mg isosorbide-5-mononitrate (once a day)]. Ann Cardiol Angeiol (Paris) 50 (6),340-350.
15. Metra (2002) BAP EIA kit. Quidel Corp., San Diego, CA, USA, 1-6.
16. Meunier PJ, Slosman DO, Delmas PD, Sebert JL, Brandi ML, Albanese C et al. (2002) Strontium ranelate: Dose-dependent effects in established postmenopausal vertebral osteoporosis - a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 87 (5),2060-2066.
17. Osteomark (2002) NTx Urine Product Description. Ostex International, Seattle, WA, USA, 1-3.
18. Piccinini F, Rovati L, Zanni A, Cagnacci A, Volpe A and Facchinetti F (2000) Indirect evidence that estrogen replacement therapy stimulates nitric oxide synthase in postmenopausal women. Gynecol Endocrinol 14 (2),142-146.
19. Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C. et al. (2005) Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90 (5),2816-2822.
20. Selby P (2004) Postmenopausal osteoporosis. Curr Osteoporos Rep 2 (3),101-106.
21. Simoncini T and Genazzani AR (2000) Raloxifene acutely stimulates nitric oxide release from human endothelial cells via an activation of endothelial nitric oxide synthase. J Clin Endocrinol Metab 85 (8),2966-2969.
22. Thatcher GR, Nicolescu AC, Bennett BM and Toader V (2004) Nitrates and NO release: Contemporary aspects in biological and medicinal chemistry. Free Radic Biol Med 37 (8),1122-1143.
23. Wimalawansa SJ (2000a) Nitroglycerin therapy is as efficacious as standard estrogen replacement therapy (Premarin) in prevention of oophorectomy-induced bone loss: A human pilot clinical study. J Bone Miner Res 15 (11),2240-2244.
24. Wimalawansa SJ (2000b) Restoration of ovariectomy-induced osteopenia by nitroglycerin. Calcif Tissue Int 66 (1),56-60.